Cargando…
Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis
BACKGROUND: Hemocoagulase batroxobin is used to prevent hemostasis or bleeding in surgical and trauma patients; however, the role of batroxobin in patients with hemoptysis is not well understood. We evaluated the risk factors and prognosis of acquired hypofibrinogenemia in hemoptysis patients treate...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922611/ https://www.ncbi.nlm.nih.gov/pubmed/36794140 http://dx.doi.org/10.21037/jtd-22-717 |
_version_ | 1784887571463012352 |
---|---|
author | Lee, Jae-Kyeong Yoon, Chang-Seok Na, Young-Ok Park, Hwa Kyung Oh, Hyung-Joo Kho, Bo-Gun Park, Ha-Young Kim, Tae-Ok Shin, Hong-Joon Kwon, Yong-Soo Kim, Yu-Il Lim, Sung-Chul |
author_facet | Lee, Jae-Kyeong Yoon, Chang-Seok Na, Young-Ok Park, Hwa Kyung Oh, Hyung-Joo Kho, Bo-Gun Park, Ha-Young Kim, Tae-Ok Shin, Hong-Joon Kwon, Yong-Soo Kim, Yu-Il Lim, Sung-Chul |
author_sort | Lee, Jae-Kyeong |
collection | PubMed |
description | BACKGROUND: Hemocoagulase batroxobin is used to prevent hemostasis or bleeding in surgical and trauma patients; however, the role of batroxobin in patients with hemoptysis is not well understood. We evaluated the risk factors and prognosis of acquired hypofibrinogenemia in hemoptysis patients treated systemically with batroxobin. METHODS: We retrospectively reviewed the medical charts of hospitalized patients who were administered batroxobin for hemoptysis. Acquired hypofibrinogenemia was defined as a plasma fibrinogen level >150 mg/dL at baseline, decreasing to <150 mg/dL after batroxobin administration. RESULTS: Overall, 183 patients were enrolled, of whom 75 had acquired hypofibrinogenemia after the administration of batroxobin. There was no statistical difference in the median age of the patients in the non-hypofibrinogenemia and hypofibrinogenemia groups (72.0 vs. 74.0 years, respectively). The patients in the hypofibrinogenemia group showed a higher rate of intensive care unit (ICU) admission (11.1% vs. 22.7%; P=0.041) and tended to have more massive hemoptysis than those in the non-hyperfibrinogenemia group (23.1% vs. 36.0%; P=0.068). The patients in the hypofibrinogenemia group further showed a higher requirement for transfusion (10.2% vs. 38.7%; P<0.000) than those in the non-hyperfibrinogenemia group. Low levels of baseline plasma fibrinogen and a prolonged and higher total dose of batroxobin were associated with the development of acquired hypofibrinogenemia. Acquired hypofibrinogenemia was associated with increased 30-day mortality [hazard ratio (HR), 4.164; 95% confidence interval (CI), 1.318–13.157]. CONCLUSIONS: The plasma fibrinogen levels in patients who were administered batroxobin for hemoptysis should be monitored, and batroxobin should be discontinued if hypofibrinogenemia occurs. |
format | Online Article Text |
id | pubmed-9922611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-99226112023-02-14 Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis Lee, Jae-Kyeong Yoon, Chang-Seok Na, Young-Ok Park, Hwa Kyung Oh, Hyung-Joo Kho, Bo-Gun Park, Ha-Young Kim, Tae-Ok Shin, Hong-Joon Kwon, Yong-Soo Kim, Yu-Il Lim, Sung-Chul J Thorac Dis Original Article BACKGROUND: Hemocoagulase batroxobin is used to prevent hemostasis or bleeding in surgical and trauma patients; however, the role of batroxobin in patients with hemoptysis is not well understood. We evaluated the risk factors and prognosis of acquired hypofibrinogenemia in hemoptysis patients treated systemically with batroxobin. METHODS: We retrospectively reviewed the medical charts of hospitalized patients who were administered batroxobin for hemoptysis. Acquired hypofibrinogenemia was defined as a plasma fibrinogen level >150 mg/dL at baseline, decreasing to <150 mg/dL after batroxobin administration. RESULTS: Overall, 183 patients were enrolled, of whom 75 had acquired hypofibrinogenemia after the administration of batroxobin. There was no statistical difference in the median age of the patients in the non-hypofibrinogenemia and hypofibrinogenemia groups (72.0 vs. 74.0 years, respectively). The patients in the hypofibrinogenemia group showed a higher rate of intensive care unit (ICU) admission (11.1% vs. 22.7%; P=0.041) and tended to have more massive hemoptysis than those in the non-hyperfibrinogenemia group (23.1% vs. 36.0%; P=0.068). The patients in the hypofibrinogenemia group further showed a higher requirement for transfusion (10.2% vs. 38.7%; P<0.000) than those in the non-hyperfibrinogenemia group. Low levels of baseline plasma fibrinogen and a prolonged and higher total dose of batroxobin were associated with the development of acquired hypofibrinogenemia. Acquired hypofibrinogenemia was associated with increased 30-day mortality [hazard ratio (HR), 4.164; 95% confidence interval (CI), 1.318–13.157]. CONCLUSIONS: The plasma fibrinogen levels in patients who were administered batroxobin for hemoptysis should be monitored, and batroxobin should be discontinued if hypofibrinogenemia occurs. AME Publishing Company 2022-12-09 2023-01-31 /pmc/articles/PMC9922611/ /pubmed/36794140 http://dx.doi.org/10.21037/jtd-22-717 Text en 2023 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Lee, Jae-Kyeong Yoon, Chang-Seok Na, Young-Ok Park, Hwa Kyung Oh, Hyung-Joo Kho, Bo-Gun Park, Ha-Young Kim, Tae-Ok Shin, Hong-Joon Kwon, Yong-Soo Kim, Yu-Il Lim, Sung-Chul Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis |
title | Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis |
title_full | Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis |
title_fullStr | Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis |
title_full_unstemmed | Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis |
title_short | Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis |
title_sort | risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922611/ https://www.ncbi.nlm.nih.gov/pubmed/36794140 http://dx.doi.org/10.21037/jtd-22-717 |
work_keys_str_mv | AT leejaekyeong riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT yoonchangseok riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT nayoungok riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT parkhwakyung riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT ohhyungjoo riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT khobogun riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT parkhayoung riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT kimtaeok riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT shinhongjoon riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT kwonyongsoo riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT kimyuil riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis AT limsungchul riskfactorsandclinicaloutcomesassociatedwithacquiredhypofibrinogenemiainpatientsadministeredhemocoagulasebatroxobinforhemoptysis |